Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 0.48 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 0.44 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.44 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.44 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.44 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.44 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL540244 | 1.00 | BLM (0.65) | BLMESR1ESR2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1322060 | 1.00 | BLM (0.65) | BLMESR1ESR2MEN1KMT2A | |
| SCHEMBL503525 | 0.98 | BLM (0.67) | BLMESR1ESR2MEN1KMT2A | |
| SCHEMBL503526 | 0.98 | BLM (0.67) | BLMESR1ESR2MEN1KMT2A | |
| SCHEMBL540243 | 0.98 | BLM (0.67) | BLMESR1ESR2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1311456 | 0.85 | SMN1; SMN2 (0.50) | BLMMEN1KMT2AKDM4EUSP2 | |
| Hydrochloric Acid SCHEMBL2210717 | 0.85 | SMN1; SMN2 (0.50) | BLMMEN1KMT2AKDM4EUSP2 | |
| Hydrochloric Acid SCHEMBL2210722 | 0.85 | SMN1; SMN2 (0.50) | BLMMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL180210 | 0.83 | BLM (0.47) | BLMMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL3647847 | 0.83 | BLM (0.65) | BLMESR1ESR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255920-A2 | COMPOSITIONS AND METHODS FOR MODULATING CANCER IN NON-HUMAN MAMMALS | Hoffman Technologies LLC (US) | 2023-10-11 | — | — | EP | claimed |
| WO-2022120039-A2 | COMPOSITIONS AND METHODS FOR MODULATING CANCER IN NON-HUMAN MAMMALS | HOFFMAN STEVEN (US) | 2022-06-09 | — | — | WO | claimed |
| EP-3968785-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Tyme, Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| WO-2020159400-A1 | PHARMACEUTICAL COMPOSITION BASED ON ALPHA-METHYL-P-TYROSINE AND METHOD OF EARLY DIAGNOSIS OF PARKINSON'S DISEASE | Общество с ограниченной ответственностью "Центр ранней диагностики нейродегенеративных заболеваний (НДЗ)" | 2020-08-06 | — | — | WO | claimed |
| EP-4255920-A2 | COMPOSITIONS AND METHODS FOR MODULATING CANCER IN NON-HUMAN MAMMALS | Hoffman Technologies LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4090329-A2 | TYROSINE DERIVATIVES FOR MODULATING CANCER | Tyme, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| EP-4072560-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | Tyme, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022120039-A2 | COMPOSITIONS AND METHODS FOR MODULATING CANCER IN NON-HUMAN MAMMALS | HOFFMAN STEVEN (US) | 2022-06-09 | — | — | WO | disclosed |
| CN-114599352-A | alpha-methyl-DL-tyrosine alkyl esters for the treatment of cancer | 迪美公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-3968785-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Tyme, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022048922-A1 | SUBSTITUTED VICINAL DIAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF PAIN | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2022-03-10 | — | — | WO | disclosed |
| EP-3964497-A1 | SUBSTITUTED VICINAL DIAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF PAIN | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2022-03-09 | — | — | EP | disclosed |
| EP-0984981-B1 | ANTI-INFLAMMATORY TYROSINE DERIVATIVES | CELLTECH THERAPEUTICS LTD (GB) | 2003-12-17 | — | — | EP | disclosed |
| US-6093696-A | N-ACETYL-D-THIOPROLINE-(O-2,6-DICHLOROBENZYL)-L-TYROSINE, FOR EXAMPLE; SELECTIVELY INHIBIT THE ALPHA 4 SUBGROUP OF INTEGRINS FROM BINDING TO THEIR LIGANDS; USE IN PROPHYLAXIS OR TREATMENT OF IMMUNE OR INFLAMMATORY DISEASES | CELLTECH THERAPEUTICS, LIMITED (GB) | 2000-07-25 | — | — | US | disclosed |
| EP-0984981-A1 | ANTI-INFLAMMATORY TYROSINE DERIVATIVES | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-03-15 | — | — | EP | disclosed |
| US-5968581-A | Dipeptide derivatives and sweetening agents | AJINOMOTO CO., INC. (JP) | 1999-10-19 | — | — | US | disclosed |
| WO-1998054207-A1 | ANTI-INFLAMMATORY TYROSINE DERIVATIVES | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-12-03 | — | — | WO | disclosed |
| CN-1199049-A | Novel dipeptide derivatives and sweetening agents | AJINOMOTO KK (JP) | 1998-11-18 | — | — | CN | disclosed |
| EP-0866073-A1 | Novel dipeptide derivatives and sweetening agents | Ajinomoto Co., Ltd. (JP) | 1998-09-23 | — | — | EP | disclosed |
| US-5331006-A | Cholecystokinin, antisecretory agents | WARNER-LAMBERT COMPANY (US) | 1994-07-19 | — | — | US | disclosed |